Experts discuss the metrics used to evaluate continuous glucose monitoring (CGM)'s comprehensive return on investment, including both cost savings and quality measure performance, and identify which ...

The following is a summary of “Evidence for improved glucose metrics and perinatal outcomes with continuous glucose ...

Here are some stocks to watch on Wednesday: ...

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

Abbott (ABT) stock in focus as the company reaffirms 2025 outlook amid tariff impact following a mixed Q1 earnings report.

Science Connected Magazine is an editorially independent, non-profit newsroom producing open-access science journalism and ...

DexCom stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food ...

U.S. stocks were lower, with the Dow Jones index dipping over 800 points on Thursday. Pricesmart reported quarterly earnings ...

announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%, 3 Dexcom ...

The Food and Drug Administration (FDA) has cleared diabetes-management firm DexCom's (DXCM) new continuous glucose monitoring ...

Continuous Glucose Monitors (CGMs) for non-diabetics. This trend sees wellness influencers and biohackers wearing medical-grade devices to track blood sugar levels, often drawing questionable ...